Seluna, a Glasgow-based MedTech startup, secured nearly €752k in funding. Gabriel Investment Syndicate led the round. This investment supports the company's AI-powered diagnostics for paediatric sleep disorders.
Advancing Paediatric Sleep Diagnostics
The funding round included contributions from Scottish Enterprise, University of Strathclyde, and STAC Invest. Seluna develops an artificial intelligence tool. This solution identifies and classifies digital biomarkers from sleep study data. It aims to tackle the underdiagnosis of childhood sleep apnoea, a condition often overlooked by broader AI diagnostics solutions.
Seluna launched an NHS validation study. This 500-patient trial takes place at the Royal Hospital for Children in Glasgow. The study validates Seluna’s proprietary Software as a Medical Device (SaMD). This technology uses machine-learning algorithms. It automatically analyses sleep study data, a process traditionally requiring manual interpretation.
The company's software addresses a condition affecting an estimated 96 million children globally. Approximately 80% of these children remain undiagnosed. While many sleep technology companies focus on adult markets, Seluna's approach focuses on explainable AI for paediatric care. This builds trust for clinical use.
Seluna plans multi-site validation. Other NHS centres will join by year-end. The company targets UK Class I classification by late 2026. US FDA Class II approval is sought by 2027. This MedTech innovation aims to set new standards.
